ArticleOphthalmology and therapy2025
Efficacy and Safety of Femtosecond Laser-Assisted Cataract Surgery with the Catalys Platform in Patients with Type 2 Diabetes and Cataract: A Prospective Cohort Study.
Article in Ophthalmology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Postoperative Flare and Corneal Endothelial Cell Loss After Eight-Chop Technique Phacoemulsification: A Prospective Observational Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionIn recent years, the continuous rise in diabetes prevalence has led to a significant increase in the number of patients with diabetic cataracts. Femtosecond laser-assisted cataract surgery (FLACS), as an innovative technology in the field of cataract treatment, has demonstrated remarkable advantages over conventional phacoemulsification (CPS) in terms of surgical precision and efficiency. However, the unique ocular pathological changes in patients with diabetes (such as fragile lens capsules, posterior synechiae of the iris, and increased risk of postoperative inflammatory reactions) pose distinct challenges for cataract surgery. Currently, there is a lack of evidence-based medical data regarding the safety and efficacy of FLACS in this specific population.
methodsIn this prospective study, 87 patients with diabetic cataract were randomized to the CPS (n = 46) and FLACS group (n = 41). Baseline characteristics and postoperative outcomes (central macular thickness [CMT], corneal thickness [CT], best-corrected visual acuity [BCVA], aqueous prostaglandin E2 [PGE2]) were analyzed. A non-diabetic control group (n = 40) underwent identical evaluations, including pupil size measurement.
resultsBaseline characteristics showed no significant differences between groups (p > 0.05). FLACS and CPS groups demonstrated comparable CMT and CT at all time points (preoperative, 1 week, 1 month, 3 months), although both groups showed increased values postoperatively versus baseline (p < 0.05). The FLACS group achieved significantly better BCVA at 1-day postoperative assessment (p < 0.05) and exhibited higher aqueous PGE2 levels (p < 0.05). Patients with diabetic cataract and non-diabetic cataract had similar anatomical and visual outcomes (p > 0.05), but diabetics maintained higher postoperative PGE2 levels following FLACS (p < 0.05). No significant difference in pupil diameter was observed between the two groups (p > 0.05).
conclusionFLACS showed comparable safety to CPS with faster visual recovery but higher PGE2 in patients with diabetic cataract, requiring close postoperative monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.